Tourmaline Bio (TRML) Competitors $18.00 +0.67 (+3.87%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TRML vs. IDYA, MESO, AGIO, APGE, AMPH, TARS, IOVA, IRON, IBRX, and WVEShould you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include IDEAYA Biosciences (IDYA), Mesoblast (MESO), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Amphastar Pharmaceuticals (AMPH), Tarsus Pharmaceuticals (TARS), Iovance Biotherapeutics (IOVA), Disc Medicine (IRON), ImmunityBio (IBRX), and Wave Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry. Tourmaline Bio vs. IDEAYA Biosciences Mesoblast Agios Pharmaceuticals Apogee Therapeutics Amphastar Pharmaceuticals Tarsus Pharmaceuticals Iovance Biotherapeutics Disc Medicine ImmunityBio Wave Life Sciences Tourmaline Bio (NASDAQ:TRML) and IDEAYA Biosciences (NASDAQ:IDYA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk. Is TRML or IDYA more profitable? IDEAYA Biosciences' return on equity of -19.42% beat Tourmaline Bio's return on equity.Company Net Margins Return on Equity Return on Assets Tourmaline BioN/A -20.97% -20.56% IDEAYA Biosciences N/A -19.42%-18.63% Does the media favor TRML or IDYA? In the previous week, IDEAYA Biosciences had 10 more articles in the media than Tourmaline Bio. MarketBeat recorded 13 mentions for IDEAYA Biosciences and 3 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 0.90 beat IDEAYA Biosciences' score of -0.01 indicating that Tourmaline Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tourmaline Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Does the MarketBeat Community favor TRML or IDYA? IDEAYA Biosciences received 124 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 71.57% of users gave IDEAYA Biosciences an outperform vote. CompanyUnderperformOutperformTourmaline BioOutperform Votes17100.00% Underperform VotesNo VotesIDEAYA BiosciencesOutperform Votes14171.57% Underperform Votes5628.43% Do institutionals & insiders believe in TRML or IDYA? 91.9% of Tourmaline Bio shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 11.0% of Tourmaline Bio shares are held by insiders. Comparatively, 3.5% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, TRML or IDYA? Tourmaline Bio has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Do analysts rate TRML or IDYA? Tourmaline Bio currently has a consensus target price of $54.00, indicating a potential upside of 200.00%. IDEAYA Biosciences has a consensus target price of $53.67, indicating a potential upside of 141.96%. Given Tourmaline Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Tourmaline Bio is more favorable than IDEAYA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00IDEAYA Biosciences 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.94 Which has better valuation & earnings, TRML or IDYA? Tourmaline Bio has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTourmaline BioN/AN/A-$42.12M-$2.82-6.38IDEAYA Biosciences$3.92M488.80-$112.96M-$2.33-9.52 SummaryIDEAYA Biosciences beats Tourmaline Bio on 9 of the 17 factors compared between the two stocks. Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRML vs. The Competition Export to ExcelMetricTourmaline BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$461.52M$2.96B$5.35B$9.06BDividend YieldN/A1.94%5.13%4.02%P/E Ratio-6.3845.5689.4817.34Price / SalesN/A358.881,251.39134.53Price / CashN/A192.9043.7535.97Price / Book1.793.975.324.80Net Income-$42.12M-$41.02M$122.60M$224.91M7 Day Performance-8.63%8.62%0.88%1.90%1 Month Performance-9.41%10.70%4.81%5.08%1 Year Performance-40.57%5.54%27.90%21.15% Tourmaline Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRMLTourmaline Bio1.8596 of 5 stars$18.00+3.9%$54.00+200.0%-42.6%$461.52MN/A-6.3844Short Interest ↑News CoverageIDYAIDEAYA Biosciences3.9781 of 5 stars$22.97-4.4%$53.67+133.6%-45.7%$1.99B$3.92M-9.8680Analyst ForecastShort Interest ↑MESOMesoblast0.7989 of 5 stars$17.18-4.0%$13.50-21.4%+894.3%$1.97B$5.90M0.0080Short Interest ↑Gap DownAGIOAgios Pharmaceuticals3.81 of 5 stars$34.30-0.3%$56.33+64.2%+49.3%$1.96B$32.87M3.02390Short Interest ↑APGEApogee Therapeutics2.5317 of 5 stars$40.91-0.3%$89.71+119.3%+17.3%$1.84BN/A-16.9091AMPHAmphastar Pharmaceuticals4.5112 of 5 stars$37.92+4.3%$60.33+59.1%-36.4%$1.82B$723.55M12.641,620Short Interest ↑TARSTarsus Pharmaceuticals1.6572 of 5 stars$47.02-10.8%$54.20+15.3%+98.6%$1.80B$129.62M-12.3450News CoverageIOVAIovance Biotherapeutics4.1614 of 5 stars$5.78-9.7%$23.00+297.9%-26.5%$1.76B$90.86M-3.88500News CoverageGap UpIRONDisc Medicine2.6323 of 5 stars$58.74-0.9%$87.50+49.0%-10.4%$1.75BN/A-14.7630Short Interest ↑News CoverageIBRXImmunityBio2.3553 of 5 stars$2.48+2.5%$13.58+447.7%-19.5%$1.73B$7.33M-2.70590Analyst ForecastOptions VolumeNews CoverageGap UpWVEWave Life Sciences4.7692 of 5 stars$11.27-2.3%$22.22+97.2%+133.3%$1.72B$53.61M-10.15240 Related Companies and Tools Related Companies IDEAYA Biosciences Alternatives Mesoblast Alternatives Agios Pharmaceuticals Alternatives Apogee Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Tarsus Pharmaceuticals Alternatives Iovance Biotherapeutics Alternatives Disc Medicine Alternatives ImmunityBio Alternatives Wave Life Sciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRML) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
